Navigation Links
Combination vaccine protects monkeys from ebola and Marburg viruses
Date:2/26/2008

An experimental, combination vaccine against Ebola and Marburg viruses using virus-like particles (VLPs) provides complete protection against infection in monkeys. Researchers from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) report their results today (Feb. 26) at the 2008 ASM Biodefense and Emerging Diseases Research Meeting in Baltimore, MD.

VLPs are one of the most promising candidates for protecting humans against Ebola and Marburg virus infections, says Dr. Kelly Warfield, a researcher at USAMRIID who presented the study. They could also be safer than other vaccine candidates.

Traditionally vaccines against viral diseases have consisted of whole viruses, either the one that causes the disease in a weakened or dead state (like the polio vaccine) or a genetically similar virus that does not usually cause disease but elicits a protective immune response. The problem with this approach is there is the risk, however small, of viral reactivation and infection.

Since the VLP vaccine does not use a whole virus, there is no chance of infection, says Warfield, who notes that some VLP-based vaccines, such as the human papillomavirus (HPV) vaccine, are already on the market.

To create the vaccine, Warfield and her colleagues infected insect cells with specially engineered baculoviruses. The infected cells then produced VLPs for either Marburg or Ebola, depending on the baculovirus, which were then purified. They mixed the two together and vaccinated the monkeys with it.

Following challenge with Ebola or Marburg virus, all the VLP-vaccinated monkeys survived challenge without clinical or laboratory signs of infection, while the control animals succumbed to the infection, says Warfield. Based on their safety profile, immunogenicity and protective efficacy, the VLPs are a leading candidate for use as a filovirus vaccine in humans.

Additionally, Warfield discovered that vaccination with one strain of Marburg VLP produced protection against 3 different strains of the virus, which is surprising. Subunit vaccines (in which only part of the virus is used) had previously not been thought to confer broad-based immunity.

Researchers are currently working on scaling up the production process and hope to begin clinical trials in humans in a few years.


'/>"/>

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology
Source:Eurekalert

Related biology technology :

1. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
4. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
5. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
6. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
7. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
8. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
9. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
10. FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
11. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... 27, 2017 , ... Oncolinx, a spin-out of the Center ... truly taken their cancer research out of this world. On April 22, 2017, ... to the International Space Station’s (ISS) U.S. National Laboratory, managed by the Center ...
(Date:4/27/2017)... Luxembourg (PRWEB) , ... April 27, 2017 , ... Mitotech ... study in Leber’s Hereditary Optic Neuropathy (LHON) patients. LHON is a rare devastating genetic ... efficacy of SkQ1 eye drops in a group of 20 patients carrying 11778, 14484 ...
(Date:4/27/2017)... ... 2017 , ... Arrowhead Publishers is pleased to announce the ... San Diego, CA on September 27-28, 2017. Leaders from the pharmaceutical, biotech, device ... the treatment of various types of pain. There are also extended networking opportunities, ...
(Date:4/27/2017)... ... April 27, 2017 , ... Sierra Instruments announces ... capillary thermal mass flow technology provide exponentially more accurate mass flow data than ... of all industrial processes—such as those involving chemical reactions, combustion, respiration, pharmaceutical, and ...
Breaking Biology Technology:
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela ... The Chancellor came to the DERMALOG stand together with the Japanese Prime ... partner country. At the largest German biometrics company the two government leaders ... iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):